Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-12-15

FDA Approved: SUBLOCADE — Supplemental Application (Indivior Inc.)

View source ↗

Summary

FDA approves a supplemental application for SUBLOCADE (buprenorphine) by Indivior Inc., expanding the approved use of the extended-release injection for opioid …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SUBLOCADE (buprenorphine extended-release)

Snippet

SUPPL AP for SUBLOCADE (BUPRENORPHINE)